Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CERE-120 · 1 trial · 1 indication
The UPDRS (Unified Parkinson's Disease Rating Scale) is a clinical rating scale that assesses the symptomatic burden of Parkinson's Disease. The scale has four main sections, and each item is scored from a 0 to a 4 (higher number is more severe manifestation). Part III is a subsection devoted to motor function, has 14 questions, resulting in a score range of 0 (unaffected) to 56 (severely affected). The scale is administered by a trained clinician, and patients were assessed in a practically defined "off" condition, 12 hours or more after the last administration of medication.
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Intracerebral administration of CERE-120 |
| 2 | SHAM_COMPARATOR | Sham Neurosurgery |
| Name | Type | Description |
|---|---|---|
| CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) | DRUG | CERE-120 5.4 x 10\^11 vg |
| Sham Surgery | PROCEDURE | Bilateral partial thickness burr holes placed, no intraparenchymal injections |
Inclusion Criteria: * Diagnosis of bilateral, idiopathic Parkinson's Disease (PD) based on UK Brain Bank criteria with motor complications despite adequate oral antiparkinsonian therapy. * At least 5 years disease duration, relative to the anticipated date of surgery, since diagnosis of PD. * Males...
CERE-120 is an investigational gene therapy developed for idiopathic Parkinson's disease. It is also known as AAV2-neurturin, or AAV2-NTN, reflecting its adeno-associated virus serotype 2 delivery of the neurturin gene. It has been studied in a completed Phase 2 clinical trial in the United States.
CERE-120 was developed for idiopathic Parkinson's disease, the most common form of Parkinson's. It is a gene therapy designed to deliver the neurturin gene to the brain. Its clinical development has focused on this single neurology indication, and it is not approved for any use.
CERE-120 was developed by Sangamo Therapeutics, Inc., which trades under the ticker SGMOQ. The company sponsored the clinical program evaluating the gene therapy in idiopathic Parkinson's disease.
CERE-120 reached Phase 2 clinical development. Its Phase 2 trial has been completed, and no trials are currently active. CERE-120 is investigational and has not been approved by the FDA for idiopathic Parkinson's disease or any other indication.
CERE-120 has been studied in one clinical trial, NCT00400634, a Phase 2 double-blind, multicenter, sham surgery controlled study in subjects with idiopathic Parkinson's disease. The trial enrolled 58 participants in the United States, included both sexes, and required a minimum age of 35 years. It is completed.
Yes. CERE-120 is also known as AAV2-neurturin, or AAV2-NTN, which stands for adeno-associated virus serotype 2 delivering the neurturin gene. Searches for either name refer to the same investigational gene therapy for idiopathic Parkinson's disease developed by Sangamo Therapeutics.